NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
51 hedge funds and large institutions have $365M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
6% more funds holding
Funds holding: 48 → 51 (+3)
0.29% more ownership
Funds ownership: 39.62% → 39.92% (+0.29%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $382M → $365M (-$17.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
+$7.1M |
| 2 |
BlackRock
New York
|
+$5.01M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$2.85M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$828K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$672K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$6.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.64M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.73M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.46M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$805K |
NGM Hedge Fund Activity: Q3 2019 in Review
51 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q3 2019, worth a combined $365M — down 4.5% from $382M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NGM positions and 9 closed out — a net gain of 3 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Peter Svennilson, adding an estimated $7.1M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $6.9M sold.
- 51 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q3 2019, up from 48 in Q2 2019.
- Funds reported $365M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q3 2019, down 4.5% quarter-over-quarter.
- 12 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of +3 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Peter Svennilson, an estimated $7.1M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q3 2019 was Foresite Capital Management IV, an estimated $6.9M sold.
Based on aggregated 13F filings for Q3 2019.